Full-Time
Life sciences strategy consulting for biopharma
$190k/yr
Boston, MA, USA + 2 more
More locations: San Francisco, CA, USA | New York, NY, USA
Hybrid
Must be able to commute to Boston, NY, or SF offices at least 40% of the time.
ClearView Healthcare Partners provides strategic consulting services exclusively for the life sciences sector, guiding pharmaceutical, biotechnology, medical devices, and diagnostics firms through decisions from discovery to commercialization. It completes project work with 100% of a dedicated team focused on a single client engagement, pairing rigorous scientific knowledge with business strategy, with many consultants holding life sciences PhDs. The firm differentiates itself through its strict one-client-per-project model, sector-only focus, and deep scientific expertise, plus international expansion to serve global clients. Its goal is to help life sciences companies grow, advance product development, and secure market access, creating value across the entire product lifecycle.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Newton, Massachusetts
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
People at ClearView Healthcare Partners who can refer or advise you
Hybrid Work Options
Remote Work Options
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Flexible Work Hours
Wellness Program
Mental Health Support
Professional Development Budget
Conference Attendance Budget
Stock Options
Company Equity
Family Planning Benefits
Fertility Treatment Support
Home Office Stipend
Phone/Internet Stipend
Parental Leave
Adoption Assistance
Meal Benefits
Relocation Assistance
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Training Programs
New findings published in Alzheimer's Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's, while ocular tests offer a non-invasive alternative for detecting at-risk patient populations NEW YORK, March 12, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) authored a first-of-its-kind paper, "Unlocking ocular biomarkers for early detection of Alzheimer's disease," providing a landscape review of ocular biomarkers as another tool, alongside blood biomarkers, to aid in the early detection of Alzheimer's disease. The paper, which was published in Alzheimer's Dementia, shares an informed perspective on the role of ocular biomarkers in the broader Alzheimer's diagnostics space and what defines a true ocular biomarker, while also highlighting the potential for ocular screening to identify at-risk patients who would otherwise go undiagnosed. The authors' assessment is based on hours of in-depth interviews with leading neurologists, ophthalmologists, optometrists, and primary care physicians from across the United States
ClearView Healthcare Partners announced a $4 million minority investment in Epistemic AI to enhance its EpistemicGPT platform, which combines AI with a vast biomedical knowledge graph. This partnership aims to improve ClearView's service offerings by integrating AI technology, enhancing research and drug development processes. The collaboration underscores a commitment to advancing biomedical research and healthcare outcomes through innovative technology solutions.
BOSTON, MA and WESTPORT, CT – 13 January 2025: ClearView Healthcare Partners, the leading life sciences strategic consultancy supporting Pharma... Read More
Digital Therapeutics Alliance is thrilled to announce the release of its latest white paper in collaboration with Clearview Healthcare Partners!
The Foundation Fighting Blindness partnered with ClearView Healthcare Partners to evaluate the impact of its funding and resources since 2005 on the clinical understanding and development of novel therapies for inherited retinal diseases (IRDs).